Results and challenges of Cytochrome P450 2D6 (CYP2D6) testing in an ethnically diverse South Florida population by Salyakina, Daria et al.
Florida International University 
FIU Digital Commons 
HWCOM Faculty Publications Herbert Wertheim College of Medicine 
8-7-2019 
Results and challenges of Cytochrome P450 2D6 (CYP2D6) 
testing in an ethnically diverse South Florida population 
Daria Salyakina 
Sharmeen Roy 
Weize Wang 
Mailin Oliva 
Rohan Akhouri 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.fiu.edu/com_facpub 
 Part of the Medicine and Health Sciences Commons 
This work is brought to you for free and open access by the Herbert Wertheim College of Medicine at FIU Digital 
Commons. It has been accepted for inclusion in HWCOM Faculty Publications by an authorized administrator of FIU 
Digital Commons. For more information, please contact dcc@fiu.edu. 
Authors 
Daria Salyakina, Sharmeen Roy, Weize Wang, Mailin Oliva, Rohan Akhouri, Ileana Sotto, Nicole Mulas, 
Rafaela Solano, Jose R. Fernandez, Stephanie Sanchez, Uzma Shamshad, Chad Perlyn, and Jennifer 
McCafferty Fernandez 
Mol Genet Genomic Med. 2019;7:e922.    |  1 of 9
https://doi.org/10.1002/mgg3.922
wileyonlinelibrary.com/journal/mgg3
Received: 15 January 2019 | Revised: 16 July 2019 | Accepted: 17 July 2019
DOI: 10.1002/mgg3.922  
O R I G I N A L  A R T I C L E
Results and challenges of Cytochrome P450 2D6 (CYP2D6) testing 
in an ethnically diverse South Florida population
Daria Salyakina1  |   Sharmeen Roy1 |   Weize Wang1 |   Mailin Oliva1 |   
Rohan Akhouri1 |   Ileana Sotto1 |   Nicole Mulas1 |   Rafaela Solano1 |    
José R. Fernández2 |   Stephanie Sanchez1 |   Uzma Shamshad1 |   Chad Perlyn1,3 |   
Jennifer McCafferty‐Fernandez1,3
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original 
work is properly cited.
© 2019 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.
1Research Institute, Nicklaus Children’s 
Hospital, Miami, Florida
2Department of Nutrition 
Sciences, University of Alabama at 
Birmingham, Birmingham, Alabama
3Herbert Wertheim College of 
Medicine, Florida International University, 
Miami, Florida
Correspondence
Daria Salyakina, Nicklaus Children’s 
Hospital Research Institute, 701 Waterford 
Way, Suite 300, Miami, FL 33126.
Email: daria.salyakina@nicklaushealth.org
Abstract
Background: This study focuses on the implementation of CYP2D6 genetic test 
profiling and the challenges associated with using standard pharmacogenetics panels 
in a diverse South Florida population.
Methods: A total of 413 participants were recruited to participate in this study 
through Nicklaus Children's Hospital. Buccal swabs were collected and tested using 
an extended CYP2D6 panel including 22 alleles. Phenotype, genotype, and allelic 
frequencies were compared among different racial and ethnic groups.
Results: The majority of participants (75.0%) self‐identified as Hispanics. Four al-
leles, CYP2D6*4, *17, *41, and *2A, showed a statistically significant difference 
between White Hispanics and Black Non‐Hispanics. Aggregate frequency of all al-
leles with decreased function varied between 2.8% and 50.0% in different racial and 
ethnic groups. Additionally, rare allele combinations were observed in this South 
Florida cohort.
Conclusions: The heterogeneity among Hispanic groups demonstrated in previous 
literature and by this study reflects the complexity of ethnicity and suggests that a 
more granular categorization is needed, one based on ancestry and migration history 
rather than primary language. Overall, we have determined that there are statistically 
significant differences in CYP2D6 allele frequencies in the distinct racial and ethnic 
populations of South Florida, demonstrating a unique genetic makeup within South 
Florida. However, overall, the frequencies of Poor Metabolizer, Normal Metabolizer, 
Intermediate Metabolizer, and Ultrarapid Metabolizer did not differ between racial 
and ethnic groups at a statistically significant level.
K E Y W O R D S
CYP2D6, ethnicity, Hispanic, intermediate metabolizers, normal metabolizers, pharmacogenetics, poor 
metabolizers, race, ultrarapid metabolizers
2 of 9 |   SALYAKINA et AL.
1 |  INTRODUCTION
Cytochrome P450 2D6 (CYP2D6) is an enzyme metabolizing 
approximately 25% of therapeutic drugs, including antide-
pressants, antipsychotics, analgesics, antitussives, beta‐ad-
renergic blocking agents, antiarrhythmics, and antiemetics 
(NIH, 2017a). This drug‐metabolizing enzyme is encoded by 
a highly polymorphic CYP2D6 gene with more than 100 vari-
ant alleles located on chromosome 22q13.1 (Daly et al., 1996; 
NIH, 2017a) (OMIM #608902, NM_001195406). Each 
CYP2D6 allele (or haplotype) is defined by a specific pro-
file of single‐nucleotide polymorphisms (SNPs), insertions, 
deletions, duplications, and multiplications (Crews, 2014). 
As allelic variants influence protein expression and activity, 
CYP2D6 polymorphisms impact the enzyme's functional ca-
pacity to metabolize therapeutic drugs. CYP2D6 alleles are 
phenotypically defined by their expected influence on overall 
CYP2D6 enzymatic activity, such as no function, decreased 
function, normal function, increased function, unknown, and 
uncertain function (Caudle, 2017). An individual's CYP2D6 
diplotype, or their combination of maternal and paternal al-
leles, comprehensively determines CYP2D6 metabolic activity 
as poor metabolizers (PMs), intermediate metabolizers (IMs), 
normal metabolizers (NMs), or ultrarapid metabolizers (UMs) 
(NIH, 2017a). An UM phenotype is a result of gene dupli-
cation or multiplication which occurs from inheriting more 
than two copies of the fully functional CYP2D6 alleles (UM) 
(Crews, 2014).
The efficacy and toxicity of a therapeutic drug metabo-
lized by CYP2D6 can differ from person‐to‐person depend-
ing on an individual's CYP2D6 genotype and phenotype. One 
example is codeine, an opioid analgesic indicated to relieve 
mild to moderate pain through codeine metabolism and mor-
phine activation by CYP2D6 enzymes (NIH, 2017b). Data 
show that CYP2D6 PMs demonstrate significantly lower 
morphine serum concentrations and analgesia in comparison 
to NMs who receive identical doses of codeine (Eckhardt et 
al., 1998). Meanwhile, CYP2D6 UMs exhibit an increased 
conversion of codeine to morphine in comparison to NMs, 
which can result in toxic concentrations of morphine and life‐
threatening adverse reactions (Ciszkowski, Madadi, Phillips, 
Lauwers, & Koren, 2009; Dalén, Frengell, Dahl, & Sjöqvist, 
1997; Gasche, 2004). For this reason, it is vital to under-
stand CYP2D6 pharmacogenetics and how CYP2D6 poly-
morphisms influence a patient's favorable or adverse clinical 
responses to drugs metabolized by CYP2D6 enzymes (NIH, 
2016).
Based on the U.S. census estimates in 2016, 67.7% of 
Miami‐Dade residents identified as Hispanic or Latino com-
pared to 17.8% nationally (U.S. Census Bureau, 2016). Given 
that the CYP2D6 allele, genotype, and phenotype frequen-
cies may differ substantially among ethnic and racial groups, 
pharmacogenetic testing may be used to personalize and 
improve treatment for diverse patient populations (NIH, 2017; 
Owusu‐Obeng et al., 2014). Studies have demonstrated that 
certain Hispanic groups have CYP2D6 alleles that are rare 
in non‐Hispanic populations (Bernard, 2006; Casner, 2005; 
Gaedigk, 2010; Luo, Gaedigk, Aloumanis, & Wan, 2005). 
However, current pharmacogenetics research focuses primar-
ily on White Non‐Hispanics (Claudio‐Campos, Duconge, 
Cadilla, & Ruaño, 2015; Ortega & Meyers, 2014; Ramos, 
Callier, & Rotimi, 2012), which may lead to a misrepresenta-
tion of allelic frequency estimates in highly diverse Hispanic 
or Latino populations, such as those in South Florida.
The genotyping of CYP2D6 involves analysis of a select 
number of known SNPs and genetic variants. However, the 
number of screened variants is inconsistent across labora-
tories, ranging from 3 to 35 alleles (Flores‐Angulo, 2015; 
Gaedigk, Bradford, Marcucci, & Leeder, 2002; Gaedigk et 
al., 1999; Kohlrausch, 2009; Leathart et al., 1998; López, 
Guerrero, Jung‐Cook, & Alonso, 2005). The inconsistencies 
in results are due to laboratories differing in test design, in-
cluding what alleles are interrogated and how the alleles are 
identified. This leaves many alleles untested and undetected, 
which may return false‐negative results (Bell, 2017; Gaedigk 
et al., 1999).
Our study focused on the unique CYP2D6 genetic pro-
file of the South Florida population. We examined the allele 
and phenotype frequencies among different combinations of 
races and ethnicities. Due to a lack of diversity in the cur-
rently available pharmacogenetics research and data, we 
hypothesized that these differences would be statistically sig-
nificant in the South Florida population.
2 |  MATERIALS AND METHODS
2.1 | Ethical compliance
Western Institutional Review Board approved the study and 
all participants and their caregivers provided consent/assent 
when appropriate.
Patients of Nicklaus Children's Hospital were recruited to 
participate in this study (N = 413). Most participants enrolled 
at the end of their visit with the neurology, plastic surgery, 
or hematology/oncology departments. Patients and family 
members attending the hospital's Cancer Center Mini Relay 
for Life were also introduced to the study and invited to par-
ticipate. All patients had to be between the ages of 1–21 years 
and reside in the South Florida area to be eligible for the 
study.
Participants were asked to provide their race as either 
White, Black, Asian, or Mixed, and categorized their eth-
nicity as Hispanic or Non‐Hispanic. There were 37 par-
ticipants (8.9%) who refused to provide this information. 
These patients were included in the analysis of total fre-
quencies of phenotypes. Buccal swabs were collected 
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for DNA extraction. All samples were genotyped at the 
Genelex® Corporation (Genelex Corporation) using an 
extended CYP2D6 (OMIM #608902, NM_001195406) 
panel with enough sensitivity to capture over 93.0%–97.0% 
of the low‐frequency PM phenotypes. Genelex® was se-
lected based on several factors including clinical decision 
support, turnaround time, breadth of the panel, and cost. 
Twenty‐two alleles were included in the panel: CYP2D6 
*1, *2, *2A, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *14A, 
*15, *17, *19, *20, *29, *35, *36, and *41.
All participants and their primary caregivers if requested 
were mailed a copy of their individual phenotype/genotype 
results. The patients were also offered a consultation with a 
genetic counselor if they wanted a detailed explanation of the 
study results.
Subsequently, genotype results were analyzed. Allelic fre-
quencies were assessed for statistically significant differences 
at a 95% confidence interval (CI) for proportions. CI was cal-
culated as p ± 1.96 × SE, where SE = sqrt(p × (1 − p)/n); p is 
the proportion of an allelic variant or a phenotype in a given 
race and ethnicity group; n is the total number of patients 
in the same group. If 95% CI did not overlap, the difference 
was determined to be statistically significant. All statistical 
analysis was performed in R. Of note, the interpretation of ac-
tivity scores by Genelex® for PMs, IMs, NMs, and UMs dif-
fered from that of Clinical Pharmacogenetics Implementation 
Consortium (CPIC) guidelines. CPIC definitions were used 
in this study, namely, activity scores of 1.0–2.0 were consid-
ered NM.
3 |  RESULTS
Of the 413 individuals enrolled in the study, 376 provided 
information on their race and ethnicity, 75.0% identified as 
Hispanic, and 19.0%, 2.0%, and 11.0% identified their race 
as Black, Asian, and Mixed, respectively (Figure 1, Table 1). 
Most of the participants (62.0%) were White Hispanic (WH) 
followed by Black Non‐Hispanic (BNH) (16.0%). The most 
common phenotype in this cohort was NM (90%), followed 
by IM (4.0%) (Figure 2). The UM and PM phenotypes were 
equally represented at 3.0%. Of the 22 CYP2D6 alleles ex-
amined, 14 were identified in the South Florida population: 
CYP2D6*1, *2, *2A, *3, *4, *5, *6, *9, *10, *17, *29, *35, 
*36, and *41. Eight alleles from the panel were not present: 
CYP2D6*7, *8, *11, *12, *14A, *15, *19, and *20.
In total, 10 SNPs and 10 deletions/duplications were de-
tected, showing variable allele frequencies among different 
race/ethnic groups (Figure 3). There were significant differ-
ences in frequencies among participants depending on their 
race and ethnicity for four alleles: CYP2D6*4, *17, *41, and 
*2A (Figure 3). The occurrence of a no‐function allele *4, 
was more prevalent in WH (14.7%) than in BNH (2.4%). As 
a result, PM genotype combinations were only detected in 
individuals self‐identifying as White.
Aggregate frequency of all decreased function alleles 
varied between 2.8% in White Non‐Hispanic participants 
and 50.0% in Mixed Non‐Hispanics. BNH subjects when 
compared to WH had a significantly higher frequency of 
CYP2D6*17 (15.3% vs. 2.8%), while CYP2D6*41 showed 
a significant difference in the opposite direction (0.8% vs. 
7.5%). (Figure 3).
Furthermore, in our study, the normal function 
CYP2D6*2A allele was significantly more frequent in the 
WH population (17.5%) than in the BNH (6.5%).
Finally, a rare allele combination and a unique duplication 
were observed in this South Florida cohort. Specifically, we 
found a BNH individual with four copies of normal function 
including CYP2D6*1, *2A, and two *2‐like alleles. Since no 
deleterious mutations were detected, it is assumed that all four 
alleles are active, and the phenotype would be expected to be 
UM. In addition, there was one BNH (0.8%) and one WH 
(0.2%) study participant with the rare tandem allele *36‐10.
Overall, we have determined that there are statistically 
significant differences in CYP2D6 allele frequencies in 
the distinct racial and ethnic populations of South Florida, 
F I G U R E  1  Study Participants' Ethnicity and Race (N = 376 
nonmissing values). 75% identified Hispanic as their ethnicity. Most of 
the participants (62%) were White Hispanic (WH) followed by Black 
Non‐Hispanic (BNH) (16%)
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demonstrating a unique genetic makeup within South Florida. 
However, overall, frequencies of PM, NM, IM, and UM did 
not differ between racial and ethnic groups at a statistically 
significant level (Table 1). The power to detect allele fre-
quency differences between WH and BNH in our study was 
90%, but to detect differences between other less represented 
racial and ethnic groups dropped below 70%.
4 |  DISCUSSION
The distribution of phenotypes in this study was similar to 
what was previously described in literature; 4.0% IM, 3.0% 
PM, 3.0% UM, and 90.0% NM versus 2.8%, 1.9%, 4.6%, and 
92.3%, respectively (Flores‐Angulo, 2015). However, the 
distribution of allele frequencies significantly varied between 
ethnic and racial groups. Namely, alleles CYP2D6*2A, *4, 
*17, and *41 showed prominent differences among WH and 
BNH.
The nonfunctional allele CYP2D6*4 was frequent in WH 
(14.7%), but not in BNH (2.4%), aligning with other studies 
on WH participants from Cuba, Nicaragua, and Venezuela 
(Flores‐Angulo, 2015; Griman, 2012; Kohlrausch, 2009). 
Furthermore, a meta‐analysis of allele frequency studies on 
healthy Puerto Ricans determined that their *4 frequency was 
similar to White Non‐Hispanics (Bernard, 2006). The *4 al-
lelic frequencies of a Mexican‐American population revealed 
a somewhat lower frequency of 10% (Luo et al., 2005). 
Lastly, the *4 allele was less frequent in South Florida BNH 
compared to other BNH populations described in the liter-
ature (2.4% vs. 5.4%–7.8%) (Bradford, Gaedigk, & Leeder, 
1998; Cai, 2006; Gaedigk et al., 2002; Leathart et al., 1998; 
US Census Bureau, 2010a; Wan et al., 2001).
Furthermore, BNHs in this study had a greater fre-
quency of decreased function allele CYP2D6*17 (15.3%) 
compared to WHs (2.8%). These findings also align with 
reports from other studies on similar populations (Agúndez, 
Ramirez, Hernandez, Llerena, & Benítez, 1997; Bradford 
et al., 1998; Cai, 2006; Gaedigk et al., 2002; Isaza, Henao, 
López, & Cacabelos, 2000; Kohlrausch, 2009; Leathart et 
al., 1998; Llerena et al., 2012; Wan et al., 2001). However, 
other in‐depth studies are demonstrating significant vari-
ation among Hispanics. Namely, one study compared the 
presence of *17 between Cuban Mestizos, Nicaraguan 
Mestizos, and White Cubans. The allele was most prevalent 
in the Cuban Mestizos (10.2%). Meanwhile, none of the 
Nicaraguan Mestizos had *17, but 2.7% of the White Cuban 
population did (Llerena et al., 2012). Another study con-
ducted in Costa Rica analyzed three different ethnic groups: 
Mestizo, Amerindian, and Afro‐Caribbean, and demon-
strated that a greater proportion of the Afro‐Caribbean 
group (18.4%) had *17. The Mestizo and Amerindian pop-
ulations also had *17 but to a lesser extent (1.8% and 2.2% 
respectively) (Céspedes‐Garro, 2014).
Another allele with decreased function showing signif-
icant differences between South Florida's racial and ethnic 
groups was CYP2D6*41. It was found in 7.5% of WH and 
only 0.8% of BNH populations. In comparison, a Spanish 
study reported a frequency of 3.8% in WH (Fernández‐
Santander, 2010) and a study on Mexican‐Americans found 
a frequency of 9.5% (Luo et al., 2005). Furthermore, the 
T A B L E  1  CYP2D6 phenotype frequencies grouped by race and ethnicity
Frequency
White Non‐
Hispanic
White 
Hispanic
Mixed 
Non‐Hispanic
Mixed 
Hispanic
Black 
Non‐Hispanic
Black 
Hispanic
Asian 
Non‐Hispanic
Poor metabolizer 1 10 0 0 0 0 0
Intermediate metabolizer 0 9 0 0 3 0 0
Normal metabolizer 17 203 5 38 56 11 9
UltraRapid metabolizer 0 10 0 1 3 0 0
Total 18 232 5 39 62 11 9
Note: OMIM gene ID: 608902, NM_001195406.
F I G U R E  2  Phenotypes of 413 participants. OMIM gene ID: 
608902, NM_001195406
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reported frequencies of *41 in BNH populations markedly 
vary (1.8%–14.4%) (Cai, 2006; Gaedigk, 2005). Notably, 
alleles *41 and *2A were not distinguished until recently. 
Specifically, *2A involves a −1584C>G substitution while 
*41 involves a 2988G>A polymorphism (Daly et al., 1996). 
Therefore, before the 2988G>A SNP was characterized as a 
unique marker identifying *41, the sole method of differen-
tiating *41 from *2A was by testing for the absence of SNP 
1584C>G (Kennedy, 2008). Because of their similarity, not 
all prior studies tested for *41 and may have inadvertently 
reported larger frequencies of *2A in the tested populations. 
These issues have challenged the ability of researchers to 
accurately report *2A frequencies until recently (Blake, 
2007; Cai, 2006; Gaedigk et al., 1999; Gaedigk, 2005, 2008; 
Griman, 2012; Kennedy, 2004, 2008).
This study is the first to identify a CYP2D6*36‐10 allele 
in a WH participant. The tandem allele *36‐10 is prevalent 
in Japanese populations (24.2%–26.7%), but rarely detected 
among African‐Americans (0.4%), and not reported in 
White populations (Hosono, 2009; Kiyotani, 2010; Soyama 
et al., 2004; Soyama, 2006). There are insufficient data on 
Hispanics or Latinos. The combination of a decreased func-
tion allele *10 with the no‐function allele *36 is thought to 
contribute to a PM phenotype (Gaedigk, Bradford, Alander, 
& Leeder, 2006; Kiyotani, 2010). Notably, *10 has conflict-
ing data on several Puerto Rican populations. One study 
stated that *10 was found less frequently than in Caucasian 
populations, while another reported that Puerto Ricans have 
a *10 frequency similar to Caucasians (Claudio‐Campos, 
Orengo‐Mercado, et al., 2015).
Our research findings describe more accurate representa-
tions of CYP2D6*2, *2A, *17, and *41 allele frequencies in 
South Florida WH and BNH populations, and also identify 
a rare *36‐10 allele in a WH, as well a unique *2A duplica-
tion that has not been well‐described in Hispanic populations. 
Finally, CYP2D6 test results revealed that the PM phenotype 
F I G U R E  3  CYP2D6 allele frequencies grouped by race and ethnicity and enzyme activity categories with corresponding 95% CI. The 
biggest difference in allele frequencies among the “poor metabolizers” was observed for the *4 allele, varying between 2.4% and 14.7% in Black 
Non‐Hispanic and White Hispanic respectively. OMIM gene ID: 608902, NM_001195406
CYP2D6*4xN CYP2D6*5 CYP2D6*6 CYP2D6*9
CYP2D6*35 CYP2D6*36 CYP2D6*36-10 CYP2D6*4 CYP2D6*41
CYP2D6*29 CYP2D6*29xN CYP2D6*2A CYP2D6*2AxN CYP2D6*3
CYP2D6*1 CYP2D6*10 CYP2D6*17 CYP2D6*1xN CYP2D6*2
0 20 40 60 0 20 40 60 0 20 40 60 0 20 40 60
0 20 40 60
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Black Non-Hispanic
Mixed Hispanic
Mixed Non-Hispanic
White Hispanic
White Non-Hispanic
Asian Non-Hispanic
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was only found in White individuals, which could be poten-
tially explained by our low number of non‐White study par-
ticipants. These results highlight the need for data on a larger 
number of non‐White populations and ethnic minorities.
In general, the frequency data on CYP2D6 *4, *17, *41, 
and *2A in diverse populations is limited. Therefore, there is 
a need to better characterize the CYP2D6 genotype and phe-
notype variability in Hispanics and Latinos.
In addition to these frequent alleles, there may be others 
that are unique to Hispanics and Latinos that were not in-
cluded in the study panel. For example, there have been stud-
ies among Latin American, Central American, and Hispanic 
countries that have provided insight into unique allelic vari-
ants. One such study involved Mexican Mestizos, Mexican 
individuals with a mixed European and American Indian 
background. They discovered a rare variant CYP2D6*82 at 
a frequency of 2.1% (Kiyotani, 2010). The functionality of 
CYP2D6*82 is currently unknown but the origin was sug-
gested to be American Indian. Another study on a Mexican 
Mestizo population identified the normally functioning al-
lele *53 in 0.5% of the sample (Contreras, 2011). Studies 
have also identified rare no‐function CYP2D6*31 and *40 
in several Hispanic populations. For instance, the allele 
*31, associated with PMs, was discovered in two Spaniards 
and two Puerto Ricans (Gaedigk, 2010). Another geno-
typing study on a Puerto Rican cohort noted two individ-
uals: one who had *31 and one with *40 (Gaedigk, 2010). 
Approximately 2.1%, 3.7%, and 0.6% of the Hispanic res-
idents of Miami‐Dade County reported themselves in the 
2010 Census as Mexican, Puerto Rican, and Spanish, re-
spectively (US Census Bureau, 2010b). Allele *31 was not 
tested in this study, but it would be beneficial to include 
it in future pharmacogenomic panels for the South Florida 
population.
Although there were significant variations in allelic fre-
quencies, no statistically significant differences in phenotype 
frequency were observed among the South Florida cohort 
evaluated in this study. This may be a result of an insuffi-
cient sample size of non‐Hispanic and non‐White cohorts 
and future larger studies are needed to prove this hypothesis. 
Past studies demonstrated that the frequency of CYP2D6 phe-
notypes among several Hispanic and Latino groups differs 
from that of White non‐Hispanics across the Americas. A 
retrospective review of phenotype frequencies among eth-
nic groups found that the frequency of PMs in non‐Hispanic 
Whites from the Americas is 7.7%, while the frequency of 
PMs among Colombians, Mexicans, Panamanians, and 
Nicaraguans is markedly lower (6.6%, 3.2%, 2.2%–4.4%, 
and 3.6% respectively) (Bernard, 2006). At the same time, 
Mexican Mestizo had a frequency of PM phenotype similar 
to the white Spanish population (10%) (López et al., 2005).
The review of UM phenotype frequencies also demon-
strated ethnicity‐based differences. Hispanic UMs were less 
common when compared to white American UMs (1.7% vs. 
4.3%) (Bernard, 2006). The heterogeneity among Hispanic 
groups demonstrated in previous literature and by this study 
reflects the complexity of ethnicity and suggests that a more 
granular categorization is needed, one based on ancestry and 
migration history rather than primary language. These results 
prove once again that Hispanic ethnicity is not homogeneous, 
but rather is a mix of various populations with very diverse 
genetic backgrounds.
This study has a few limitations. WH and BNH were the 
two largest population groups in the study. It is therefore not 
surprising that the only statistically significant differences 
found were between the two ethnic groups with the largest 
sample sizes. It is possible that there are additional frequency 
differences among other groups in this population, but this 
study is underpowered to detect them. In addition, the race 
and ethnicity used in this study were based on self‐reported 
records by the study participants. These records may be im-
precise and biased. Future studies should include design and 
resources to allow for genetic confirmation or verification of 
perceived ancestry.
Overall, our findings suggest that in predominantly 
Hispanic or Latino populations, the assumption that allelic 
and phenotype distributions are similar to less diverse pop-
ulations may be inaccurate. As a result, pharmacogenetic 
panels designed for less diverse populations may not be ap-
propriate for Hispanic populations. If the subject of a test 
has an allele that was not included in the panel, they risk im-
proper classification of their CYP2D6 function. For example, 
CYP2D6*31, *49, *50, *54, *55, *59, and *84 all translate 
to decreased or no function, however, they were not tested 
in this study and are not included in most commercial pan-
els. It is currently not known whether these alleles are prev-
alent in Hispanics or Latinos. If a patient had any of these 
alleles, they would be incorrectly classified as NM. That 
could explain the markedly lower rates of PM previously re-
ported in Hispanics (Bernard, 2006). Thus, pharmacogenetic 
test results would be more useful and accurate if laborato-
ries sequenced the entire CYP2D6 gene, rather than selected 
polymorphisms. As a whole, sequencing would also provide 
a better depiction of the allelic variation within underrep-
resented communities (Barron et al., 2016; Bernard, 2006; 
Claudio‐Campos, Orengo‐Mercado, et al., 2015; Ortega & 
Meyers, 2014). Importantly, minority groups are predicted to 
become the majority by 2044, with a quarter being Hispanic 
(Colby & Ortman, 2015). As the nation's diversity grows, it 
is critical that the available pharmacogenetic tests reflect the 
heterogeneity of the population.
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